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Abstract 
This paper describes methodologies, based on sector field inductively-coupled plasma 
mass spectrometry (SF-ICP-MS), and their application in the holistic study of the fate of 
Pt in human cell populations following treatment with cis- or oxaliplatin and combination 
treatments. Pt-DNA adduct formation data at several time points has been determined in 
the leukocytes from patients undergoing Pt-based chemotherapy demonstrating 
significant inter-patient variability and excellent reproducibility of the assay. The 
sensitivity of the technique enabled quantitation of as little as 0.2 Pt adducts per 106 
nucleotides using 10 µg of patient DNA. Further, the first ever reported in vivo sub-
cellular Pt fractionation data on a patient sample is presented indicating the feasibility of 
applying the methods presented here in a clinical environment.  For in vitro studies, three 
cell models were used: A549 human lung adenocarcinoma epithelial cells were exposed 
to 50 μM cisplatin for 1 hour; HCA7 human colorectal cancer cells were treated with 
either FOLFOX (200 μM 5-fluorouracil, 200 μM folinic acid and 50 μM oxaliplatin) or 
50 μM oxaliplatin; and HT29 human colorectal cancer cells were treated with 50 μM 
oxaliplatin in combination with 20 μM methaneseleninic acid, CH3SeO2H (MSA). The 
cells were harvested and either the DNA extracted and/or a commercially available kit 
used to fractionate the treated cells into four sub-cellular compartments. Each of the sub-
cellular fractions and extracted DNA were digested separately, evaporated to dryness and 
reconstituted in 2% nitric acid for analysis by SF-ICP-MS.  The sub-cellular Pt 
distribution for cisplatin treated A549 cells was shown to be as follows: ~70% localized 
in the cytosol, ~17 % in the membrane and membrane localized fraction, ~9 % in the 
nuclear fraction and ~4 % in the cytoskeletal fraction. Both FOLFOX and oxaliplatin 
treated HCA7 cells showed comparable sub-cellular Pt distributions, and Pt-DNA adduct 
formation was similar for the oxaliplatin and FOLFOX treatments with adduct yields of 
5.6 and 5.5 adducts per 106 nucleotides respectively. It was found that the combination of 
oxaliplatin with 20 μM MSA did not change the distribution of Pt or significantly alter its 
accumulation in the cytosol of the HT29 cells. Mass balance experiments showed a > 99 
% recovery of the total Pt in the sub-cellular fractions. These experiments are the first to 
provide such a detailed quantitation of Pt-drug partitioning and they show that the Pt 
broadly follows the total protein content of the individual compartments with the majority 
being scavenged in the cytosol compartment.  
 
Key Words: Cisplatin, Oxaliplatin, FOLFOX, Pt-DNA adducts, Sub-cellular 
Fractionation, ICP-MS, Mass Balance, Selenium, Clinical samples  
Introduction 
Rosenberg first reported the chemotherapeutic action of diamminedichloroplatinum(II), 
commonly known as cisplatin, in 1969 and since then it has arguably become the most 
prominent metal complex in medicine.  It is by far the most widely employed anti-cancer 
agent in the treatment of head, neck, lung, ovarian, testicular and cervical cancer [1] and 
its great success is perhaps best exemplified in that, with early diagnosis, it has been 
shown to be a near total cure for testicular cancer [2]. Despite the success, there are 
concerns regarding its side effects such as neurotoxicity and damage to the kidneys [3-6]. 
The acquired resistance of some cancer cells to the drug following initial treatment and 
the inability to confer lasting remissions have also been recognised as major drawbacks 
of cisplatin chemotherapy [7-10].  As a result, the identification and characterisation of 
other metal complexes for cancer treatment is ongoing.  
Oxaliplatin, a complex consisting of a platinum centre bound to two bidentate ligands; 
oxalate and a diaminocyclohexane (dach), is a third-generation anti-tumour agent that is 
used for treating colorectal cancer [11-13] and has been successful in treating cell lines 
and tumours that have developed resistance to cisplatin and other platinum based anti-
cancer drugs [12-14]. Oxaliplatin also produces side effects such as haematological 
suppression and neuropathy [15], although it has been suggested that these effects are less 
pronounced relative to cisplatin [13, 14, 16]. At the molecular level both Pt-drugs are 
believed to kill cancer cells by binding to DNA, their ultimate pharmacological target 
[17-19]. Not surprisingly therefore, many experimental and theoretical studies have 
focused on Pt attachment to DNA [20-23]. Oxaliplatin undergoes ligand exchange in 
physiological conditions where the oxalate ligand is replaced by two chloride ligands to 
form [Pt(dach)(Cl)2] [24]. It is widely accepted that upon the [Pt(dach)(Cl)2] complex, or 
cisplatin, entering a cell, the semi-labile chlorides in either species are replaced by water 
ligands [25, 26]. This does not readily occur in the blood stream, where the drugs are 
introduced intravenously, due to the high concentration of free circulating chloride ions 
[25, 26].  It is by undergoing this partial hydrolysis in the cell that these drugs are 
activated forming primarily cis-[PtCl(H2O)(NH3)2]+ and cis-[Pt(H2O)2(NH3)2]2+ in the 
case of cisplatin and [Pt(dach)(H2O)2] 2+ in the case of oxaliplatin [12, 27, 28]. After 
penetrating the nucleus of the cell, the central Pt metal in these ions can undergo further 
ligand substitution reactions with DNA producing several mono-dentate adducts, as well 
as many intra- and inter-strand cross links, between the N7 atoms of the purine bases.  
The intra-strand DNA complex, where Pt bridges adjacent guanine bases, is by far the 
most dominant DNA adduct with either cisplatin or oxaliplatin comprising ~ 65% of the 
total [29-32]. The resulting distortion of the DNA structure signals cell cycle arrest, 
allowing for repair and, if the damage levels are high enough, subsequent apoptosis [7, 
19]. Intracellular Pt content is considered to play a significant role in cytotoxicity and 
resistance.  Several studies have investigated the accumulation of cisplatin in various 
cancer cell types and have examined the cellular uptake of the drug as a function of 
exposure time [23, 33-37].  Decreased intracellular Pt concentration due to increased 
efflux or decreased drug uptake was also shown to cause cisplatin resistance [7, 38-42]. 
After entering the blood stream cisplatin or oxaliplatin can react with molecules 
containing strong electron donor groups (e.g. thiols, carbonyl oxygens and amino 
nitrogens) such as human serum albumin, one of the most abundant proteins in blood 
plasma [43-48]. These reactions partially inactivate the drugs and reduce their sub-
cellular uptake.  In order to reduce such interactions and to improve the cellular uptake, 
recent studies have focused on modifying the structure of the drugs or combining them 
with other molecules such as bafilomycin and methyl-β-cyclodextrin to improve their 
permeability through cell membranes [23, 34-37]. Inside the cell, a plethora of ligands 
other than DNA are available to compete for the platinum, it is thus not surprising that 
only a very small fraction of either intracellular cisplatin or oxaliplatin binds to their 
pharmacological target [49].  The isolation and quantification of these scarce Pt-DNA 
complexes has been the subject of many recent reports [19, 22, 23, 36]. Non-DNA 
interactions not only account for the majority of the intra-cellular adducts formed by the 
Pt-drugs, thus reducing their efficacy, but there is also strong evidence suggesting that 
such adducts are responsible for induced resistance in cancer cells [50-52]. Key among 
these cellular adducts are Pt complexes with the cytoplasmic ligand γ-
glutamylcysteinylglycine (glutathione or GSH) [53]. The levels of GSH have been 
reported to be elevated in cisplatin resistant tumour cells [54].  It is therefore believed 
that GSH complexes with cisplatin are not only a major cellular sink of the drug, causing 
its inactivation by forming stable covalent adducts [53, 55], but also prevent cisplatin 
from binding to DNA.  Recent studies discovered a clear positive correlation between the 
resistance to cisplatin and elevated cellular levels of GSH in several ovarian cancer cells 
[55]. The extent of Pt-GSH binding in cisplatin has been reported to account for 
approximately 60% of its intracellular concentration [53], while a more recent report 
reduced this dramatic figure suggesting that it does not exceed 20% [28].  
FOLFOX is a common combination chemotherapy used for treatment of patients with 
colorectal cancer and is considered one of the most effective treatments for metastatic 
colorectal cancer. Oxaliplatin has been shown to improve the efficacy of the 5-FU and 
folinic acid combination [56], however the synergistic effect between these drugs is not 
well understood. While it is widely accepted that Pt-based drugs, such as oxaliplatin, 
produce their pharmacological action by forming various types of adducts with the DNA 
(Pt-DNA adducts), the effect of 5-FU and folinic acid on the sub-cellular distribution of 
oxaliplatin in the cell has not been investigated. Other combination treatments include 
selenium, an essential trace element in the human body, and a common supplement taken 
during chemotherapy [57] which has recently been shown to have some anti-cancer 
properties. [58] Methyl selenol (CH3SeH) has been suggested to be a highly important 
metabolite involved in selenium anti cancer action [59]. Moreover, it has been shown that 
selenium supplements can help to reduce certain toxicities such as leukopenia and 
nephrotoxicity related to platinum-based chemotherapy [60]. However, the interaction 
between selenium and Pt-based drugs is still not well studied. 
To date only very few reports have focused on the sub-cellular fractionation of Pt 
complexes within a cell [22, 28, 61-64]. Out of these, even fewer examined the sub-
cellular fractionation post uptake by cancer cells [28, 62, 64]  while to the best of our 
knowledge none was conducted on patient samples in clinical studies.  In all previous 
studies, the sub-cellular fractions examined were obtained at the cost of destroying, and 
thus losing all information pertaining to other sub-cellular components, thus no holistic 
picture has ever been obtained.  
Gibson et al. [28, 65] noted that there is a lack of methodologies that are able to provide 
information on metallodrugs in cell models at biologically significant concentrations. 
However, using the high sensitivity and accurate, precise and fast quantitation provided 
by inductively coupled plasma mass spectrometry (ICP-MS), some progress has been 
made. Thus Pt has been determined in a variety of clinical samples [66] and ICP-MS has 
been used specifically for the determination of Pt in samples from patients following Pt-
based drug chemotherapy.[67-70] Nevertheless, the determination of Pt in order to further 
understanding of the pharmacokinetics and pharmacodynamcis of Pt-based chemotherapy 
remains a challenge due to the very low Pt concentrations and often limited sample 
amounts. 
At the point of care, clinicians currently have no prior knowledge of individual patient 
pharmaco-dynamic or pharmaco-genetic response and therefore patients receive a 
standardized dose based on body surface area and kidney function. It has been estimated 
that as a result, approximately 40% of patients [71] receive inappropriate doses. This 
work is ultimately aimed at meeting this unmet need in oncology, to personalize doses in 
Pt-based drug chemotherapy. 
Using the exquisite sensitivity, species independent response and linearity of state-of-the-
art sector field, inductively coupled plasma mass spectrometry (SF-ICP-MS), we present 
patient data on Pt-DNA adduct formation, individual patient variability in adduct yield, 
the persistence of those adducts over extended treatment cycles and evidence of their 
repair. Further (as detailed below), we demonstrate a methodology by which a holistic 
picture of drug partitioning in the leukocytes of patients undergoing chemotherapy was 
obtained. 
Further in vitro studies employed various cell models to provide data on drug partitioning 
into the four major cellular compartments: a) cytosolic, b) membrane and membrane-
localized, c) soluble nucleic and DNA-associated nuclear and d) cytoskeletal fractions 
[72]; the effect of the commonly used FOLFOX (200 μM 5-fluorouracil, 200 μM folinic 
acid and 50 μM oxaliplatin) cocktail on the partitioning of oxaliplatin and adduct 
formation; and the effect of selenium supplementation on oxaliplatin partitioning and 
adduct formation. All proteins, with the exception of those in the cytoskeletal fraction, 
were obtained in their native state to prevent any disturbance to the Pt-protein complexes 
prior to analysis.  The data are not statistically powered as for a clinical trial, but are 
presented as proof of concept that the methodology can produce data hitherto unavailable 
by any other means. 
 
Experimental 
Materials 
All chemicals, tissue culture media and reagents used were purchased from Sigma (Poole, 
UK), unless otherwise stated.  HNO3 (70%) and H2O2 (30%) were purchased from Romil 
Ltd. (Cambridge, UK).  Cisplatin (CAS registry number: 15663-27-1) was obtained from 
Teva UK. Oxaliplatin was obtained from Sanofi-Synthelabo Limited (Guildford, UK).  
Folinic acid (FA) and 5-Fluoro Uracil (5-FU) were obtained from Medac UK.    
ProteoExtract® sub-cellular proteome extraction kit for mammalian cells was obtained 
from Merck KGaA (UK). QIAGEN Blood & Cell Culture DNA Midi Kit was purchased 
from Qiagen (Crawley, UK). 
In vivo clinical Pt-DNA adducts determination: 
Collection of blood samples from patients 
Ethical approval for the study was granted by the Leicestershire and Rutland Research 
Ethics Committee (no. 6106). After obtaining informed consent, 10-15 ml blood samples 
were collected from twenty eight patients undergoing treatment with different platinum 
based combination chemotherapy at three time points and at different treatment cycles. 
The patients were treated with FOLFOX (5-fluorouracil, folinic acid and oxaliplatin), 
EOX (epirubicin, oxaliplatin and capecitabine), Oxali/Cape (oxaliplatin and 
capecitabine), ECX (epirubicin, cisplatin and capecitabine), or ECF (epirubicin, 
fluorouracil and cisplatin) combination chemotherapy. The notional Pt drug dose for each 
of these regimens were 85 mg /m2 every 2 weeks, 12 cycles, for oxaliplatin in FOLFOX 
combination, 130 mg/ m2 every 3 weeks, 6 cycles, for oxaliplatin in EOX and Oxali/Cape 
combinations, and 50 mg/ m2 every 3 weeks, 6 cycles, for cisplatin in ECX and ECF 
combinations. However, not all patients received the same dose at each cycle as the 
starting dose had to be reduced (typicall by 20%) in some cases due to drug toxicity.  The 
sampling time points, chosen for patient convenience, were: immediately prior to drug 
administration, and one hour and twenty four hours after drug administration.  Blood was 
taken in vials containing sufficient potassium EDTA to achieve a concentration of 1.2 - 2 
mg EDTA/ml blood after collection (SARSTEDT, Germany). Samples were kept at room 
temperature and the leukocytes were isolated as quickly as possible.  
Leukocyte isolation 
Leukocytes were isolated using Ficoll-Paque PLUS (GE Healthcare, UK). The blood was 
diluted with an equal volume of RPMI 1640 media (Sigma-Aldrich, UK) and then 10 ml 
of the blood/RMPI mixture was carefully layered on top of 12 ml Ficoll-paque PLUS and 
centrifuged at 1700 rpm for 30 minutes at room temperature. The inter-phase layer was 
collected with a Pasteur pipette and was washed twice in RPMI 1640 media. Cells were 
frozen and stored at -80 C in RPMI media containing 20% foetal calf serum (FCS) and 
10% DMSO. 
DNA extraction from leukocytes 
DNA was extracted from isolated leukocytes using Blood & Cell Culture DNA Kit from 
QIAGEN (Crawley, UK) according to the manufacturer’s protocol. Briefly, the frozen 
leukocyte samples were thawed and washed twice with PBS. Cells were then lysed and 
the cell nuclei were collected as pellets following centrifugation. Protein in samples was 
digested using Protease enzyme and DNA was extracted from samples using DEAE ion 
exchange cartridges. The final DNA samples were dissolved in water before determining 
the DNA content by measuring the UV absorbance at 260 nm wavelength. Samples were 
stored at -20°C for subsequent SF-ICP-MS analysis. 
Cell culture conditions  
A549 human lung adenocarcinoma epithelial cell line, a non-small cell lung cancer 
(NSCLC) cell line, HT29 and HCA7 human colorectal cancer cell lines used in this study 
were purchased from the American Type Culture Collection (ATCC, USA). A549 cells 
have been reported to be resistant to cisplatin and therefore represent a suitable model for 
examining the holistic fate of the platinum [73]. RPMI 1640 media containing L-
glutamine with 10 % FCS were used to grow the A549 cells used in this study.  HT29 and 
HCA7 cells were cultured in Dulbecco's modified Eagle's media supplemented with 10% 
FCS and 4500 mg/L glucose.  All the cells were grown in an incubator at 37 oC in a 5% 
CO2 atmosphere. No antibiotics were added to the media. Cells were tested and 
confirmed as mycoplasma contamination free. 
Drug treatment of cells 
A549 cells were incubated with freshly prepared solutions of cisplatin in media (50 µM) 
for 1 hour at 37ºC before washing with PBS and collection by trypsinisation.  HCA7 cells 
were incubated with oxaliplatin (50 µM) or FOLFOX (50 µM oxaliplatin, 200 µM 5-FU 
and 200 µM FA). HCA7 cells were cultured in duplicate to study the sub-cellular 
fractionation of Pt as well as Pt-DNA adduct formation.   HT29 cells were treated with 
either oxaliplatin (50 µM) or oxaliplatin (50 µM) in combination with methaneseleninic 
acid, CH3SeO2H (MSA) (20 µM).  Non-drug treated control cells were also processed 
alongside the drug treated cells. To study Pt-DNA adduct formation, DNA was also 
isolated from the HCA7 cells that were treated with oxaliplatin and FOLFOX using 
QIAGEN Blood & Cell Culture DNA Midi Kit.  
 Sub-cellular fractionation 
To obtain the sub-cellular fractions an extraction procedure with the ProteoExtract® sub-
cellular proteome extraction kit (Merck KGaA  (UK))  was performed on the harvested cell 
pellets described in detail elsewhere [72]. An equal volume of harvested cell pellets was used 
to  carry  out  a  mass  balance  experiment  and  the  Pt  content  of  the  drug  treated  whole  cell 
extracts was determined. 
Sample preparation 
The digestion method employed was originally described by Yamada et al. [74] and 
modified by Kerr [75]. Briefly, 0.8 volume of 70 % nitric acid was added to 1 volume of 
each extracted DNA sample or sub-cellular fraction and heated at 70 ºC for one hour 
followed by the addition of 0.8 volume of 30 % hydrogen peroxide and heating at the 
same temperature for a further 4 hours.  In the case of whole cell extracts, used for mass 
balance, 300 μl each of 70 % nitric acid and 30 % hydrogen peroxide were used in the 
same digestion procedure.  The resulting digest was evaporated to dryness under a gentle 
stream of high purity argon gas then reconstituted in 300 μl or 1 ml, for the extracted 
DNA samples and sub-cellular fractions respectively, of 0.5 ppb Eu solution, used as 
internal standard, in 2 % nitric acid. Prior to SF-ICP-MS analysis, the whole cell extract 
samples were diluted by 100 fold with 2 % nitric acid. 
Instrumental and measurement procedure 
Analyses were performed on a sector-field ICP-MS instrument (ThermoFisher Element 2 
XR, Bremen, Germany). The instrument was fitted with a cyclonic spray chamber (Glass 
Expansions, Victoria, Australia) and a PFA nebuliser (PFA-ST Elemental Scientific, 
Omaha, USA). Typical operating parameters for the instrument are summarised in Table 
1. The low resolution peak jump mode, with 13 passes per run and 3 runs per sample, was 
used to measure 195Pt and 153Eu which was used as an internal standard (see below).  In 
the case of DNA sample analysis, 31P was also measured in the medium resolution mode.  
The determination of Pt by ICP-MS is potentially subject to spectral and non-spectral 
interferences. However, spectral interferences from metal oxide formation such as 
hafnium oxide is not significant in biological samples since the Hf background is lower 
than the Pt background [76-78]. Furthermore, metal oxide formation can be minimized by 
optimizing the gas flow rate and plasma ionization conditions. Hence, the conditions 
were optimised before each analysis for maximum sensitivity and minimum metal oxide 
formation. Non-spectral interferences, from the complex sample matrix, that affected the 
Pt signal were overcome by digesting the matrix prior to the analysis and using Eu as an 
internal standard. 
Use of Eu as an internal standard 
Eu was selected as a suitable internal standard for this work because it gave the best 
performance in improving the quantification of both Pt and P in different concentrations 
of the DNA sample matrix compared to 40 other elements screened and evaluated for this 
purpose.  Eu produced the lowest %RSD values for intensity ratios to both Pt (Eu:Pt) and 
P (Eu:P) , and the lowest relative % error in Pt quantification  in varying concentrations 
of sample matrix.  
 Calculation of the number of Pt-DNA adducts per number of DNA nucleotides 
The number of Pt-DNA adducts was calculated using the Pt concentrations obtained from 
the SF-ICP-MS data. The number of DNA nucleotides, however, could be obtained by 
two ways, either from the DNA concentrations determined by UV or from P data 
obtained from SF-ICP-MS. In this study, the latter method was used to determine the 
number of DNA nucleotides since it was found that using the Pt/P ratio to calculate the 
number of Pt-DNA adducts per nucleotide was a more robust approach and gave more 
reproducible values. The Pt/P was robust against matrix effects and produced very 
consistent data in different DNA matrix concentrations. The use of the Pt/P ratio would 
also have cancelled errors due to sample losses during the sample preparation in a similar 
way to improving quantification by using analyte/internal standard ratios. Moreover, 
using the P data to calculate the number of DNA nucleotides (each phosphorus atom 
corresponds to one nucleotide) is in principle more accurate than using the DNA 
concentrations from the UV data which requires averaging the RMM’s of the four 
different DNA nucleotides.  
Results and Discussion 
Figure 1 and Figure 2 present the Pt-DNA adduct formation data obtained from twenty 
eight patients on various cisplatin or oxaliplatin based chemotherapies. Data are 
presented (whenever it was possible to obtain patient samples), at three time points and at 
different treatment cycles. The time points chosen for patient convenience were: 
immediately prior to Pt-drug administration, one hour and twenty four hours after Pt-drug 
administration.  All patients on the first cycle of treatment either did not exhibit any Pt-
DNA adduct formation, prior to Pt-drug administration, or such adducts (from 
environmental Pt) were present at levels below the instrumental limit of detection.  The 
lower limit of quantitation (LLOQ) of Pt in white blood cells from the clinical blood 
samples was determined to be 0.2 Pt adducts per 106 nucleotides using 10 µg of patient 
DNA. This figure is lower than reported values of 1.9 to 3.0 Pt-DNA adduct per 106 
nucleotides determined by the post-labelling assay [79] in white blood cells of patients 
after cisplatin chemotherapy. It is clear from Figure 1 and Figure 2 that the method 
employed here allows for the measurement of in vivo Pt-DNA adducts formed due to the 
administration of a variety of Pt-drugs at clinical concentrations. Excellent reproducibility 
was obtained, as shown in Table 2, whenever patient DNA was available in sufficient 
quantity to allow for duplicate measurements to be performed.  The reproducibility of the 
results was shown for several different samples from patients on various treatment 
regimes, on different treatment cycles and using varying amounts of DNA, as detailed in 
Table 2. The excellent agreement of the Pt-adduct data from these replicate analyses 
illustrates the reproducibility of the DNA extraction and digestion procedures employed, 
in addition to the instrumental analysis.  More remarkably, the sensitivity of this method 
allowed for the detection and quantitation of Pt-DNA adducts, prior to Pt-drug 
administration, in patients who had had previous chemotherapeutic cycles.  The presence 
of these Pt-DNA adducts indicates their persistence in the DNA in patients’ white blood 
cells for the length of time between each Pt-drug administration cycle which is typically 
two to three weeks. This carry over phenomenon may play a role in patients’ response to 
chemotherapy and should be investigated further. 
The variability between patients in Pt-DNA adduct formation shown in Figure 1 and 
Figure 2 can be attributed to numerous causes including the varying doses and 
combination therapies administered or the different types of cancers presented.  This 
variability however, also indicates that some host-specific factors may have a role to play. 
The Pt-DNA adduct levels at one hour and twenty four hours after drug administration 
were not substantially different for most of the patients studied. Work elsewhere has 
shown DNA adduct formation peaking at around 6 hours after Pt-drug administration [80, 
81]. Sample collection at this time point, however, was not convenient to patients in this 
cohort and thus it was not possible to obtain intermediate time point data. The inter-
patient variability in the ratio of Pt-DNA adducts at the one hour and twenty four hour 
time points shown in Figure 1 and Figure 2, although only small for most patients, may 
explain individual variability in tolerance to side effects caused by chemotherapy and 
increased resistance to the Pt-drug. Of particular interest is patient 7, see Figure 1 , who 
presented with a T3N1 gastro-oesophageal adenocarcinoma and showed the highest Pt-
DNA adduct formation among the cisplatin group.  This patient experienced high levels 
of toxicity, however exhibited a complete pathological response upon surgical resection 
after chemotherapy. Alternatively, patient 24, see Figure 2, who showed the highest 
levels of Pt-DNA adduct formation at 1 hour among the oxaliplatin group also 
demonstrated the most significant reduction of Pt-DNA adducts after twenty four hours. 
This substantial DNA repair capacity may have been responsible for this patient’s 
increased tolerance to side effects as compared with others in the same group. 
 Whilst the data presented are from a small number of patients, some qualitative 
observations can be drawn indicating a need for further study.  Most noteworthy of these 
was that comparing the adduct data with clinical notes there was prima facie evidence for 
some patients of a positive correlation between adduct formation and toxicity. Since the 
majority of patients receiving Pt are receiving palliative care, toxicity is the main driver 
of clinical pathway and predictive markers for toxicity are of considerable potential 
clinical value. Further, in some cases, it may be that a critical concentration of Pt-DNA 
adducts is required to cause cell apoptosis, but that exceeding this critical concentration, 
without a substantial DNA repair capacity, could lead to significant toxicities.  
Importantly these data also provide support for the hypothesis that the nuclear DNA from 
healthy white blood cells can in some circumstances be a useful model for predicting 
drug performance in tumour tissue. 
These observations in conjunction with the current hypothesis that Pt-non DNA 
interactions may correlate with toxicity led us to examine the sub-cellular Pt-drug 
partitioning in several human cell types treated in vitro with a variety of Pt-drugs. Figure 
3 shows a snapshot of the Pt distribution (percentage of Pt) in each of the four sub-
cellular fractions of the different types of human cancer cells after treatment with Pt for 1 
hour.  Excellent reproducibility of these results was demonstrated by performing one of 
the sub-cellular fractionation experiments in six replicates as shown in Figure 3.  The Pt 
sub-cellular distribution was not only internally reproducible in replicate measurements 
but also across different cell cultures of the same cancer cell line after incubation with the 
same Pt drug.  The Pt sub-cellular distribution observed was also very comparable across 
the different cancer cell lines and the variety of Pt-drugs used in this study, as shown in 
Figure 3, while the Pt signals obtained for all non-drug treated control samples were 
below the instrumental detection limit. 
 
Table 3 lists typical protein contents in each of the fractions obtained by the extraction 
procedure described here as a percent of the total proteins obtained from various human 
cells. Comparing these data with those in Figure 3 shows a strong correlation between Pt 
and protein abundance as might be expected given the variety of potential binding sites 
available.  The cytosolic fraction contains many highly abundant proteins and therefore it 
is perhaps not surprising that these fractions were shown to contain the largest sub-
cellular concentrations of Pt, accounting for about 70% of the Pt-drug incorporated into 
the various cancer cells.  This figure is in agreement with previous fluorescence work 
showing 81-86 % of the intracellular concentration of a platinum rhodamine-123 complex 
ending up in the cytosol of a SCC-25 cell (human squamous carcinoma cell line) 24 hours 
after exposure [64]. Another study employing graphite furnace atomic absorption 
detection showed the cytosolic fractions of healthy rat kidney and liver cells to contain 62 
% and 89 % respectively of cisplatin 24 h after injection [63]. These percentages are 
actually significantly higher than the corresponding 30-50% protein content of the 
cytosol. This suggests that protein content is not the sole factor affecting sub-cellular Pt 
distribution.  The presence of other small cytoplasmic molecules with high affinity to Pt-
drugs, such as glutathione [28], as well as possible preferential Pt binding could be 
among the reasons for such a favourable sub-cellular Pt partitioning.  It is also possible 
that some of the Pt-drug, upon penetration of cellular walls, remains free and unbound to 
biological ligands.  Following the extraction procedure employed here most, if not all, of 
any such unbound Pt species would be collected in the cytosolic fractions. 
The nuclear fractions are of special interest as they contain the DNA, the ultimate 
pharmacological target of the Pt-drugs.  These fractions were shown to contain no more 
than 9% of the total Pt incorporated in any of the various Pt-drug treated cancer cells used 
in this study irrespective of the type of cancer cell or the kind of Pt-drug used in cell 
treatment.  However, the nuclear fractions obtained here not only contained DNA but all 
nuclear material such as RNA, chromosomes, nucleoplasm and histones, all of which 
contain electron donor groups making them potential ligands for the Pt-drugs.    This is 
reflected in data from several previous reports suggesting that Pt-DNA complexes 
account for about 1 % of the total Pt incorporated in cells [78, 82, 83]. The partitioning 
assay affords opportunity to establish whether the reported synergy from combining 
oxaliplatin, 5-FU and folinic acid in the FOLFOX regimen could be related to changes in 
Pt distribution in the cell or adduct formation. The data presented in Figure 3 shows a 
very similar sub-cellular distribution of Pt in the HCA7 human colorectal cancer cells 
upon their treatment with the oxaliplatin or FOLFOX. Further, the Pt-DNA adduct 
formation was similar in both cases yielding 5.6 and 5.5 adducts per 106 nucleotides 
respectively. While the sub-cellular distribution and Pt-DNA adduct formation data are 
all snapshots at an incubation time of 1 hour, such comparable results support the view 
that other factors such as up- and down-regulations of drug transporters and over 
expression of glutathione play a major role in the synergistic action of FOLFOX drug 
combination [84]. The partitioning assay was also applied to study the effect of Se 
supplementation combined with oxaliplatin. However, due to the high reactivity of 
methyl selenol, MSA was used in this work to generate the more reactive species in situ.  
Figure 4 shows the measured sub-cellular Pt distribution, averaged over six very 
reproducible replicate analyses, in multiple HT29 human colorectal cancer cell cultures, 
each after their incubation either with a combination of 20 µM MSA and 50 µM 
oxaliplatin or with only 50 µM oxaliplatin for one hour.  Comparison of this data, 
obtained with and without the addition of MSA under the same conditions, showed no 
statistical significant difference in the observed distribution of the Pt when Se was 
present. Selenium is a potential competitor with Pt for the available binding sites and thus 
could change the Pt distribution, but this was not observed in these pilot experiments. 
The amount of sub-cellular Pt-drug lost due to the cell fractionation procedure employed 
here was investigated in order to validate the data.  Equal volumes of cells, treated and 
untreated with Pt-drugs, were used to establish a Pt mass balance against the fractionated 
counterparts.  These samples were not fractionated into sub-cellular components but 
rather subjected to harsh whole cell digestion conditions, evaporated to dryness  and 
made up to the same volume of 2 % nitric acid used for each of the fractions of the sub-
cellular experiments.  The whole cell extracts were then diluted 98.5 times in 2 % nitric 
acid prior to analysis by ICP-MS.  The Pt content of cisplatin treated whole cell extracts 
for example was determined to be 11.5 ng/106  cells, see Table 4; this value compares 
well with a recent study reporting a sub-cellular Pt concentration of 10 ng/106 cells when 
~ 3 x 106 A2780 cisplatin resistant cells were exposed to 50 µM cisplatin for 1 hour [23]. 
The determined value for the cisplatin treated whole cell extracts compared very 
favourably with the sum of the Pt content in all four corresponding cisplatin treated sub-
cellular fractions obtained here at 11.5 ng/106 cells, presented in Table 4. This yielded a 
Pt recovery of >99 % which was typical of all mass balance experiments performed and 
provides confidence in the procedure employed. Such high Pt recovery also allows for the 
possibility of further separation/speciation of the fractions and identification of individual 
proteins or families of proteins binding to Pt.  
The sub-cellular fractionation in vivo of a patient sample on cycle 9 of a FOLFOX 
chemotherapeutic regime was carried out to test the feasibility of the fractionation 
method employed here in a clinical environment, see Figure 5. Here there was evidence 
of continued drug migration into the cells over 24 hours, excepting for the cytoskeletal 
fraction. The results obtained clearly indicate that this method is able to detect sub-
cellular Pt concentrations in patient samples prior to, one hour after, and twenty four 
hours after FOLFOX administration as is shown in Figure 5.  This is the first ever 
reported sub-cellular fractionation and Pt determination on an in vivo clinical sample. The 
same trend was observed as for the in vitro studies on cancer cell lines which further 
supports the hypothesis that the white blood cells behave similarly to cancer cells in 
terms of Pt-drug partitioning. 
Conclusion 
Sector-field ICP-MS has made it possible to determine the number of Pt-DNA adducts 
formed in white blood cells of patients on a variety of different Pt-drug based 
chemotherapies.  The detection and quantitation of Pt-DNA adducts prior to Pt-drug 
administration in patients who had previous chemotherapeutic cycles was also possible.  
Significant variability between patients in Pt-DNA adduct formation was found, which 
may be partially due to host-specific factors, in some cases this correlated with either 
efficacy, or toxicity, or both.  Some inter-patient variability in the ratio of Pt-DNA 
adducts at one hour and twenty four hour post drug administration was shown and there 
was evidence to suggest that a substantial DNA repair capacity may be correlated with 
increased tolerance to side effects.  
Combining the SF-ICP-MS methodology with a cell fractionation procedure allowed, for 
the first time, the determination of the entire sub-cellular Pt distribution within several 
human cancer cell lines following in vitro exposure to a variety of Pt-drugs.  The Pt sub-
cellular distribution was internally reproducible in replicate measurements and across 
different cell cultures of the same cancer cell line after incubation with the same Pt drug.  
The Pt sub-cellular distribution observed was also very comparable across the different 
cancer cell lines and the variety of Pt-drugs used in this study.  The Pt sub-cellular 
partitioning data presented was shown to broadly follow the sub-cellular protein 
distribution of several typical human cells.  The cystolic fractions in the Pt-drug treated 
cells, however, were shown to contain an elevated intracellular Pt concentration relative 
to the corresponding protein content. The presence of other non-protein, cytoplasmic 
molecules with high affinity to Pt-drugs, such as glutathione, as well as possible 
preferential Pt binding were suggested to be among the reasons for such a favourable sub-
cellular Pt partitioning.  The addition of selenium (in the form of CH3SeO2H) during cell 
incubation with oxaliplatin after 1 hour did not change the distribution of Pt or 
significantly alter its accumulation in the cytosol. The amount of sub-cellular Pt-drug lost 
due to the cell fractionation procedure employed here was investigated by mass balance 
experiments yielding typical Pt recovery values of >99%.    
The first ever in vivo sub-cellular Pt fractionation data on a patient sample was reported 
and shows the feasibility of applying the methods presented here in a clinical 
environment.  Gaining a holistic picture of drug partitioning will be a valuable step 
towards understanding the pharmacokinetic response of individual patients to Pt-based 
chemotherapy both in terms of drug efficacy and the prediction of unwanted side effects. 
The methodology has been applied here to Pt-drugs but it can equally be applied to any 
metallo-drug or those containing hetero atoms such as Br or I. 
 
Figure  1  Pt‐DNA  adduct  formation  data  obtained  from  ten  patients  on  cisplatin  based  combination 
chemotherapy.   Patients 1‐9 were on epirubicin, cisplatin and capicitabine combination therapy (ECX).  
Patient 10 was on epirubicin, fluorouracil and cisplatin combination therapy  (ECF).   Data  is presented 
whenever blood samples were available at three time points:  immediately prior to drug administration 
(white bars), one hour post (dark grey) and twenty four hours post (light grey) drug administration. 
0.00
0.40
0.80
1.20
1.60
2.00
1.1 1.3 2.4 3.4 4.1 4.3 4.4 5.1 6.6 7.3 8.3 9.2 10.1 10.
Pt
 ad
du
ct
s p
er
 10
6
DN
A n
uc
le
ot
id
es
Patient ID. Cycle Number
ECX ECF
 Figure  2  Pt‐DNA  adduct  formation  data  obtained  from  eighteen  patients  on  oxaliplatin  based 
combination chemotherapy.  Patient 11 was on capecitabine and oxaliplatin combination (OC).  Patients 
12‐21  were  on  5‐fluorouracil,  folinic  acid  and  oxaliplatin  (FOLFOX)  while  patients  22‐28  were  on 
epirubicin, oxaliplatin and capicitabine combination chemotherapy (EOX).  Data is presented whenever 
blood samples were available at  three  time points:    immediately prior  to drug administration  (white 
bars), one hour post (dark grey) and twenty four hours post (light grey) drug administration. 
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Figure 3 Relative concentrations determination in each of the four sub‐cellular fractions obtained using 
the  sub‐cellular  fractionation  procedure  after  1  hour  drug  treatment.  Square  hatched  bars  indicate 
HCA7 colorectal cancer cells incubated with 50 µM oxaliplatin, light grey bars indicate HCA7 colorectal 
cancer cells incubated with FOFLOX (50 µM oxaliplatin, 200 µM 5‐fluorouracil and 200 µM folinic acid), 
dark grey bars  indicate A549  lung cancer cells  incubated with 50 µM cisplatin, diagonal hatched bars 
indicate HT29 colorectal cancer cells  incubated with 50 µM oxaliplatin. The error bars represent t‐test 
values at 95% confidence level for n=6 independently prepared samples. 
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Figure 4 Relative Pt concentration determined  in each of the sub‐cellular fractions of the HT29 human 
colorectal  cancer  cells  obtained  using  the  sub‐cellular  fractionation  procedure  after  1  hour  drug 
treatment. Light grey bars  indicate  incubation with 50 µM oxaliplatin and 20 µM MSA, dark grey bars 
indicate  incubation  with  only  50  µM  oxaliplatin.  The  error  bars  represent  t‐test  values  at  95% 
confidence level for n=6 independently prepared samples. 
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Figure 5 In vivo Pt concentration determined in each of the sub‐cellular fractions of lymphocyte samples 
obtained from a patient on cycle 9 of FOLFOX chemotherapy. The samples were collected from the 
patient immediately pre‐, 1 hour post‐ and 24 hour post‐infusion of the chemotherapy.   
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Table 1 Typical conditions for SF‐ICP‐MS 
Parameter Value 
ICP Radio Frequency (RF) power 1250 W 
Cool gas flow rate 15.5 L min-1 
Auxiliary gas flow rate 0.82 L min-1 
Nebuliser gas flow rate 1.13 L min-1 
Sample uptake rate 80 μL min-1 
Sample cone Ni 
Skimmer cone Ni 
Detection mode Triple mode 
Resolution Low (Pt and Eu) and Medium (P) 
 
   
Table 2. Pt‐DNA adduct formation data for clinical samples. 
Patient.Cycle Time point Replicate 
number 
Drug DNA 
(µg) 
Pt adduct per 106 
nucleotides 
2.4 24 h 1 ECX 29 0.63 
  2 ECX 6 0.66 
      
16.1 1 h 1 FOLFOX 16 0.85 
  2 FOLFOX 28 1.03 
  3 FOLFOX 43 1.03 
      
16.9 24 h 1 FOLFOX 10 2.98 
  2 FOLFOX 9 3.19 
      
24.1 1 h 1 EOX 28 5.58 
  2 EOX 28 5.38 
      
24.1 24 h 1 EOX 7 2.36 
  2 EOX 7 2.27 
 
   
Table 3 Typical protein percentages in each sub‐cellular fraction obtained from various human cells 
following extraction using the commercial sub‐cellular fractionation kit used in this study[85] 
Cell type (human) Cytosol  Membranes Nucleus  Cytoskeleton 
Liver carcinoma HEPG2  53% 31% 10% 6% 
Mamma carcinoma MCF7 44% 32% 17% 7% 
Osteosarcom SAOS2 36% 41% 17% 6% 
Epithelial carninoma A431 33% 45% 13% 9% 
 
  
Table 4. Pt concentration determined  in each of the sub‐cellular fractions and the whole cells of A549 
lung cancer cells after 1 hour drug treatment.  
Fraction Pt concentration (ng Pt/106 cells) 
Cytosol 8.41
Cell membrane/ organelle 2.13
Nucleus 0.59
Cytoskelton 0.37
Total  11.50
Whole Cells 11.51
 
   
References 
[1] S.E. Sherman, S.J. Lippard, Structural aspects of platinum anticancer drug 
interactions with DNA, Chem. Rev. 87 (1987) 1153-1181.  
[2] S. Culine, Chimiothérapie des tumeurs germinales métastatiques du testicule de bon 
pronostic, Oncologie 10 (2008) 446-450.  
[3] L. Ta, Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons 
correlates with platinum-DNA binding, Neurotoxicology 27 (2006) 992-1002.  
[4] P.J. O'Dwyer, J.P. Stevenson, S.W. Johnson, Clinical Status of Cisplatin, Carboplatin 
and Other Platinum-Based Antitumor Drugs, in: B. Lippert. (Eds.), Cisplatin: Chemistry 
and Biochemistry of a Leading Anticancer Drug, Wiley-VCH, 1999, 29-70.  
[5] M.H. Hanigan, P. Devarajan, Cisplatin nephrotoxicity: molecular mechanisms, 
Cancer Ther 1 (2003) 47-61.  
[6] E.R. Jamieson, S.J. Lippard, Structure, Recognition, and Processing of 
Cisplatin−DNA Adducts, Chem. Rev. 99 (1999) 2467-2498.  
[7] M. Kartalou, J.M. Essigmann, Mechanisms of resistance to cisplatin, Mutat. Res. 
Fundam. Mol. Mech. Mugag 478 (2001) 23-43.  
[8] V. Brabec, J. Kasparkova, Modifications of DNA by platinum complexes: Relation to 
resistance of tumors to platinum antitumor drugs, Drug Resist Updat 8 (2005) 131-146.  
[9] P. Heffeter, U. Jungwirth, M. Jakupec, C. Hartinger, M. Galanski, L. Elbling, M. 
Micksche, B. Keppler, W. Berger, Resistance against novel anticancer metal compounds: 
differences and similarities, Drug Resist Updat 11 (2008) 1-16.  
[10] P. Borst, S. Rottenberg, J. Jonkers, How do real tumors become resistant to 
cisplatin?, Cell Cycle 7 (2008) 1353-1359.  
[11] L.E. Ta, L. Espeset, J. Podratz, A.J. Windebank, Neurotoxicity of oxaliplatin and 
cisplatin for dorsal root ganglion neurons correlates with platinum–DNA binding, 
NeuroToxicology, 27 (2006) 992-1002.  
[12] S. Arnould, I. Hennebelle, P. Canal, R. Bugat, S. Guichard, Cellular determinants of 
oxaliplatin sensitivity in colon cancer cell lines, Eur. J. Cancer 39 (2003) 112-119.  
[13] G.M. Almeida, T.L. Duarte, W.P. Steward, G.D.D. Jones, Detection of oxaliplatin-
induced DNA crosslinks in vitro and in cancer patients using the alkaline comet assay, 
DNA Repair, 5 (2006) 219-225.  
[14] S.G. Chaney, S.L. Campbell, B. Temple, E. Bassett, Y. Wu, M. Faldu, Protein 
interactions with platinum–DNA adducts: from structure to function, J. Inorg. Biochem. 
98 (2004) 1551-1559.  
[15] R. Mandal, M.B. Sawyer, X.-. Li, Mass spectrometry study of hemoglobin-
oxaliplatin complexes in colorectal cancer patients and potential association with 
chemotherapeutic responses, Rapid Communications in Mass Spectrometry 20 (2006) 
2533-2538.  
[16] E. Raymond, S. Faivre, S. Chaney, J. Woynarowski, E. Cvitkovic, Cellular and 
molecular pharmacology of oxaliplatin, Mol. Cancer. Ther. 1 (2002) 227-235.  
[17] S.G. Chaney, S.L. Campbell, E. Bassett, Y. Wu, Recognition and processing of 
cisplatin- and oxaliplatin-DNA adducts, Crit. Rev. Oncol. 53 (2005) 3-11.  
[18] Y. Jung, S.J. Lippard, Direct cellular responses to platinum-induced DNA damage, 
Chem. Rev. 107 (2007) 1387-1407.  
[19] D. Wang, S.J. Lippard, Cellular processing of platinum anticancer drugs, Nat. Rev. 
Drug Discov. 4 (2005) 307-320.  
[20] E. Björn, Y. Nygren, T.T. Thi Nhu Nguyen, C. Ericson, M. Nöjd, P. Naredi, 
Determination of platinum in human subcellular microsamples by inductively coupled 
plasma mass spectrometry, Anal Biochem 363 (2007) 135-142.  
[21] E. Volckova, L.P. Dudones, R.N. Bose, HPLC determination of binding of cisplatin 
to DNA in the presence of biological thiols: Implications of dominant platinum-thiol 
binding to its anticancer action, Pharm. Res. 19 (2002) 124-131.  
[22] C. Lottner, R. Knuechel, G. Bernhardt, H. Brunner, Distribution and subcellular 
localization of a water-soluble hematoporphyrin–platinum(II) complex in human bladder 
cancer cells, Cancer Lett. 215 (2004) 167-177.  
[23] P. Marqués-Gallego, G.V. Kalayda, U. Jaehde, H.d. Dulk, J. Brouwer, J. Reedijk, 
Cellular accumulation and DNA platination of two new platinum(II) anticancer 
compounds based on anthracene derivatives as carrier ligands, J. Inorg. Biochem. 103 
(2009) 791-796.  
[24] J.M. Woynarowski, W.G. Chapman, C. Napier, M.C.S. Herzig, P. Juniewicz, 
Sequence- and Region-Specificity of Oxaliplatin Adducts in Naked and Cellular DNA, 
Mol Pharmacol 54 (1998) 770-777.  
[25] J. Kozelka, Molecular origin of the sequence-dependent kinetics of reactions 
between cisplatin derivatives and DNA, Inorganica Chimica Acta 362 (2009) 651-668.  
[26] F. Arnesano, G. Natile, Mechanistic insight into the cellular uptake and processing 
of cisplatin 30 years after its approval by FDA, Coord. Chem. Rev. In Press, Corrected 
Proof (2009) 2070-2081.  
[27] D.V. Deubel, Factors governing the kinetic competition of nitrogen and sulfur 
ligands in cisplatin binding to biological targets, J. Am. Chem. Soc. 126 (2004) 5999-
6004.  
[28] Y. Kasherman, S. Sturup, D. Gibson, Is glutathione the major cellular target of 
cisplatin? A study of the interactions of cisplatin with cancer cell extracts, J. Med. Chem. 
52 (2009) 4319-4328.  
[29] J. Reedijk, Improved understanding in platinium antitumour chemistry, Chem. 
Commun. (1996) 801.  
[30] Z. Guo, P.J. Sadler, Metals in Medicine, Angew. Chem. Int. Ed Engl. 38 (1999) 
1512-1531.  
[31] S.M. Cohen, S.J. Lippard, Cisplatin: from DNA damage to cancer chemotherapy, 
Prog. Nucleic Acid Res. Mol. Biol. 67 (2001) 93-130.  
[32] T.W. Hambley, Platinum binding to DNA: structural controls and consequences, J. 
Chem. Soc. , Dalton Tans. (2001) 2711-2718.  
[33] P. Ilinski, B. Lai, Z. Cai, W. Yun, D. Legnini, T. Talarico, M. Cholewa, L.K. 
Webster, G.B. Deacon, S. Rainone, D.R. Phillips, A.P. Stampfl, The direct mapping of 
the uptake of platinum anticancer agents in individual human ovarian adenocarcinoma 
cells using a hard X-ray microprobe, Cancer Res. 63 (2003) 1776-1779.  
[34] A.E. Egger, C. Rappel, M.A. Jakupec , C.G. Hartinger, P. Heffeter, B.K. Keppler, 
Development of an experimental protocol for uptake studies of metal compounds in 
adherent tumor cells, J. Anal. At. Spectrom. 24 (2009) 51-61.  
[35] R.M. Xing, Characterization and cellular uptake of platinum anticancer drugs 
encapsulated in apoferritin, J. Inorg. Biochem. 103 (2009) 1039-1044.  
[36] D. Garmann, A. Warnecke, G.V. Kalayda, F. Kratz, U. Jaehde, Cellular 
accumulation and cytotoxicity of macromolecular platinum complexes in cisplatin-
resistant tumor cells, J. Controlled Release 131 (2008) 100-106.  
[37] M. Salerno, Impact of intracellular chloride concentration on cisplatin accumulation 
in sensitive and resistant GLC4 cells, J. Biol. Inorg. Chem. 14 (2009) 123-132.  
[38] A. Ghezzi, M. Aceto, C. Cassino, E. Gabano, D. Osella, Uptake of antitumor 
platinum(II)-complexes by cancer cells, assayed by inductively coupled plasma mass 
spectrometry (ICP-MS), J. of Inorg. Biochem. 98 (2004) 73-78.  
[39] P.A. Andrews, S.B. Howell, Cellular pharmacology of cisplatin: perspectives on 
mechanisms of acquired resistance, Cancer Cell 2 (1990) 35-43.  
[40] J. Holford, P.J. Beale, F.E. Boxall, S.Y. Sharp, L.R. Kelland, Mechanisms of drug 
resistance to the platinum complex ZD0473 in ovarian cancer cell lines, Eur. J. Cancer 36 
(2000) 1984-1990.  
[41] Z. Chen, M. Mutoh, T. Sumizawa, T. Furukawa, M. Haraguchi, A. Tani, N. Saijo, T. 
Kondo, S. Akiyama, An Active Efflux System for Heavy Metals in Cisplatin-Resistant 
Human KB Carcinoma Cells, Exp. Cell Res. 240 (1998) 312-320.  
[42] M. Mishima, G. Samimi, A. Kondo, X. Lin, S.B. Howell, The cellular pharmacology 
of oxaliplatin resistance, Eur. J. Cancer 38 (2002) 1405-1412.  
[43] K.R. Grigoryan, M.G. Azanuryan, N.A. Bagramyan, L.G. Grvorkyan, S.A. 
Markaryan, Spectroscopic determination of binding between human serum albumin and a 
platinum(II) dimethylsulfoxide complex, J. Appl. Spectros. 75 (2008) 593-596.  
[44] I. Takahashi, T. Ohnuma, S. Kavy, S. Bhardwaj, J.F. Holland, Interaction of human 
serum albumin with anticancer agents in vitro, Br. J. Cancer 41 (1980) 602-608.  
[45] N. Ohta, D. Chen, S. Ito, T. Futo, Effect of trans-diamminedichloroplatinum(II) on 
human serum albumin: conformational changes through partial disulfide bond cleavage, 
Int. J. Pharm. 118 (1995) 85-93.  
[46] A.I. Ivanov, J. Christodoulou, J.A. Parkinson, K.J. Barnham, A. Tucker, J. 
Woodrow, P.J. Sadler, Cisplatin binding sites on human albumin, J. Biol. Chem. 273 
(1998) 14721-14730.  
[47] B.P. Espósito, R. Najjar, Interactions of antitumoral platinum-group metallodrugs 
with albumin, Coord. Chem. Rev. 232 (2002) 137-149.  
[48] A. Warnecke, I. Fichtner, D. Garmann, U. Jaehde, F. Kratz, Synthesis and biological 
activity of water-soluble maleimide derivatives of the anticancer drug carboplatin 
designed as albumin-binding prodrugs, Bioconjug. Chem. 15 (2004) 1349-1359.  
[49] V. Cepeda, M.A. Fuertes, J. Castilla, C. Alonso, C. Quevedo, J.M. Perez, 
Biochemical mechanisms of cisplatin cytotoxicity, Anticancer Agents Med. Chem. 7 
(2007) 3-18.  
[50] C.L. Litterst, V.G. Schweitzer, Covalent binding of platinum to renal protein from 
sensitive and resistant guinea pigs treated with cisplatin: possible role in nephrotoxicity, 
Res. Commun. Chem. Pathol. Pharmacol. 61 (1988) 35-48.  
[51] S. Akiyama, Z.S. Chen, T. Sumizawa, T. Furukawa, Resistance to cisplatin, 
Anticancer Drug Des. 14 (1999) 143-151.  
[52] V. Brabec, J. Kasparkova, Molecular aspects of resistance to antitumor platinum 
drugs, Drug Resist Updat 5 (2002) 147-161.  
[53] T. Ishikawa, F. Ali-Osman, Glutathione-associated cis-
diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia 
cells. Molecular characterization of glutathione-platinum complex and its biological 
significance, J. Biol. Chem. 268 (1993) 20116-20125.  
[54] A.K. Godwin, A. Meister, P.J. O'Dwyer, C.S. Huang, T.C. Hamilton, M.E. 
Anderson, High resistance to cisplatin in human ovarian cancer cell lines is associated 
with marked increase of glutathione synthesis, Proceedings of the National Academy of 
Sciences of the United States of America 89 (1992) 3070-3074.  
[55] P. Mistry, L.R. Kelland, G. Abel, S. Sidhar, K.R. Harrap, The relationships between 
glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan 
in eight human ovarian carcinoma cell lines, Br. J. Cancer 64 (1991) 215-220.  
[56] T. Andre, C. Boni, L. Mounedji-Boudiaf, M. Navarro, J. Tabernero, T. Hickish, C. 
Topham, M. Zaninelli, P. Clingan, J. Bridgewater, I. Tabah-Fisch, A. de Gramont, 
Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant 
Treatment of Colon Cancer (MOSAIC) Investigators, Oxaliplatin, fluorouracil, and 
leucovorin as adjuvant treatment for colon cancer N. Engl. J. Med. 350 (2004) 2343-
2351.  
[57] A. Molassiotis, P. Fernadez-Ortega, D. Pud, G. Ozden, J.A. Scott, V. Panteli, A. 
Margulies, M. Browall, M. Magri, S. Selvekerova, E. Madsen, L. Milovics, I. Bruyns, G. 
Gudmundsdottir, S. Hummerston, A.M. Ahmad, N. Platin, N. Kearney, E. Patiraki, Use 
of complementary and alternative medicine in cancer patients: a European survey, Ann. 
Oncol. 16 (2005) 655-663.  
[58] M. Suzuki, M. Endo, F. Shinohara, S. Echigo, H. Rikiishi, Differential apoptotic 
response of human cancer cells to organoselenium compounds, Cancer Chemother. 
Pharmacol. 66 (2010) 475-484; 484.  
[59] M.P. Rayman, Selenium in cancer prevention: a review of the evidence and 
mechanism of action, Proc. Nutr. Soc. 64 (2005) 527-542.  
[60] Y. Hu, Y. Chen, Y. Zhang, M. Zhou, X. Song, B. Zhang, L. Luo, P. Xu, Y. Zhao, Y. 
Zhao, G. Cheng, The protective role of selenium on the toxicity of cisplatin-contained 
chemotherapy regimen in cancer patients, Biol. Trace Elem. Res. 56 (1997) 331-341.  
[61] S.K. Mauldin, G. Gibbons, S.D. Wyrick, S.G. Chaney, Intracellular 
Biotransformation of Platinum Compounds with the 1,2-Diaminocyclohexane Carrier 
Ligand in the L1210 Cell Line, Cancer Res. 48 (1988) 5136-5144.  
[62] M.E. Leibbrandt, G.H. Wolfgang, A.L. Metz, A.A. Ozobia, J.R. Haskins, Critical 
subcellular targets of cisplatin and related platinum analogs in rat renal proximal tubule 
cells, Kidney Int. 48 (1995) 761-770.  
[63] R.P. Sharma, I.R. Edwards, cis-Platinum: subcellular distribution and binding to 
cytosolic ligands, Biochem. Pharmacol. 32 (1983) 2665-2669.  
[64] B.A. Teicher, S.A. Holden, J.L. Jacobs, M.J. Abrams, A.G. Jones, Intracellular 
distribution of a platinum-rhodamine 123 complex in cis-platinum sensitive and resistant 
human squamous carcinoma cell lines, Biochem. Pharmacol. 35 (1986) 3365-3369.  
[65] D. Gibson, The mechanism of action of platinum anticancer agents—what do we 
really know about it? Dalton Trans. (2009) 10681.  
[66] Z. Yang, X.D. Hou, B.T. Jones, Determination of platinum in clinical samples, Appl. 
Spectrosc. Rev. 37 (2002) 88.  
[67] G.J. Veal, J. Errington, M.J. Tilby, A.D. Pearson, A.B. Foot, H. McDowell, C. 
Ellershaw, B. Pizer, G.M. Nowell, D.G. Pearson, A.V. Boddy, UKCCSG Pharmacology 
Working Group, Adaptive dosing and platinum-DNA adduct formation in children 
receiving high-dose carboplatin for the treatment of solid tumours Br. J. Cancer 96 (2007) 
725-731.  
[68] B.W. Cooper, G.J. Veal, T. Radivoyevitch, M.J. Tilby, H.J. Meyerson, H.M. 
Lazarus, O.N. Koc, R.J. Creger, G. Pearson, G.M. Nowell, D. Gosky, S.T. Ingalls, C.L. 
Hoppel, S.L. Gerson, A phase I and pharmacodynamic study of fludarabine, carboplatin, 
and topotecan in patients with relapsed, refractory, or high-risk acute leukemia, Clin. 
Cancer Res. 10 (2004) 6830-6839.  
[69] D. Pozebon, V.L. Dressler, A. Matusch, J.S. Becker, Monitoring of platinum in a 
single hair by laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS) 
after cisplatin treatment for cancer, Int. J. Mass Spectrom. 272 (2008) 57-62.  
[70] J.G. Morrison, P. White, S. McDougall, J.W. Firth, S.G. Woolfrey, M.A. Graham, 
D. Greenslade, Validation of a highly sensitive ICP-MS method for the determination of 
platinum in biofluids: application to clinical pharmacokinetic studies with oxaliplatin, J. 
Pharmaceut. Biomed. 24 (2000) 1-10.  
[71] S. Dawood, B. Leyland-Jones, Pharmacology and pharmacogenetics of 
chemotherapeutic agents, Cancer Invest. 27 (2009) 482-488.  
[72] A. Abdolzade-Bavil, S. Hayes, L. Goretzki, M. Kroger, J. Anders, R. Hendriks, 
Convenient and versatile subcellular extraction procedure, that facilitates classical protein 
expression profiling and functional protein analysis, Proteomics 4 (2004) 1397-1405.  
[73] G.M. Almeida, T.L. Duarte, P.B. Farmer, W.P. Steward, G.D. Jones, Multiple end-
point analysis reveals cisplatin damage tolerance to be a chemoresistance mechanism in a 
NSCLC model: implications for predictive testing, Int. J. Cancer 122 (2008) 1810-1819.  
[74] K. Yamada, N. Kato, A. Takagi, M. Koi, H. Hemmi, One-milliliter wet-digestion for 
inductively coupled plasma mass spectrometry (ICP-MS): determination of platinum-
DNA adducts in cells treated with platinum(II) complexes, Anal. Bioanal Chem. 382 
(2005) 1702-1707.  
[75] S. Kerr, Enhancing nucleic acid detection using inductively coupled plasma mass 
spectrometry, by means of metal and nano-particle labelling, PhD Thesis, Loughborough 
University, 2008.  
[76] I. Rodushkin, E. Engstrom, A. Stenberg, D.C. Baxter, Determination of low-
abundance elements at ultra-trace levels in urine and serum by inductively coupled 
plasma-sector field mass spectrometry, Anal. Bioanal Chem. 380 (2004) 247-257.  
[77] S. Hann, G. Koellensperger, K. Kanitsar, G. Stingeder, M. Brunner, B. Erovic, M. 
Muller, C. Reiter, Platinum determination by inductively coupled plasma-sector field 
mass spectrometry (ICP-SFMS) in different matrices relevant to human biomonitoring, 
Anal. Bioanal Chem. 376 (2003) 198-204.  
[78] E. Brouwers, M. Tibben, H. Rosing, J. Schellens, J. Beijnen, The application of 
inductively coupled plasma mass spectrometry in clinical pharmacological oncology 
research, Mass Spectrom. Rev. 27 (2008) 67-100.  
[79] M.J.P. Welters, M. Maliepaard, A.J. Jacobs-Bergmans, R.A. Baan, J.H.M. Schellens, 
J. Ma, W.J.F. Van der Vijgh, B.J.M. Braakhuis, A.M.J. Fichtinger-Schepman, Improved 
3 2P-postlabelling assay for the quantification of the major platinum-DNA adducts, 
Carcinogenesis 18 (1997) 1774.  
[80] G. Weber, J. Messerschmidt, A.C. Pieck, A.M. Junker, A. Wehmeier, U. Jaehde, 
Ultratrace voltammetric determination of DNA-bound platinum in patients after 
administration of oxaliplatin, Anal. Bioanal. Chem. 380 (2004) 58.  
[81] E.E.M. Brouwers, M. Tibben, D. Pluim, H. Rosing, H. Boot, A. Cats, J.H.M. 
Schellens, J.H. Beijnen, Inductively coupled plasma mass spectrometric analysis of the 
total amount of platinum in DNA extracts from peripheral blood mononuclear cells and 
tissue from patients treated with cisplatin, Anal. Bioanal. Chem. 391 (2008) 577-585.  
[82] C.R. Centerwall, K.A. Tacka, D.J. Kerwood, J. Goodisman, B.B. Toms, R.L. 
Dubowy, J.C. Dabrowiak, Modification and Uptake of a Cisplatin Carbonato Complex by 
Jurkat Cells, Mol Pharmacol 70 (2006) 348-355.  
[83] J. Reedijk, Why Does Cisplatin Reach Guanine-N7 with Competing S-Donor 
Ligands Available in the Cell? Chem. Rev. 99 (1999) 2499-2510.  
[84] D. Theile, S. Grebhardt, W.E. Haefeli, J. Weiss, Involvement of drug transporters in 
the synergistic action of FOLFOX combination chemotherapy, Biochem. Pharmacol. 78 
(2009) 1366-1373.  
[85] Merck Chemicals, ProteoExtract® Subcellular Proteome Extraction Kit, 
http://www.merck-chemicals.co.uk/life-science-research/proteoextract-subcellular-
proteome-extraction-kit/EMD_BIO-539790/p_xdCb.s1ORVMAAAEjpxp9.zLX 
(accessed 7/11/2010, 2010).  
 
